• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000538.SZ
Share

Bitcoin USD Price Stocks

CN¥ 50.6Last Updated 12.06.2026

Issuer Rating

7/7
Performance

Strong

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 13.21B

CN¥ 50.6
Key Takeaways

Risk factor

Negligible price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating globally and domestically within China, Yunnan Baiyao Group Co., Ltd. specializes in the pharmaceutical industry. Its diverse portfolio encompasses health supplements, a wide array of medications, medical devices, traditional Chinese medicine ingredients, and even tea. These offerings are marketed under various brand identities, including Yunnan Baiyao, Yunfeng, Tong Qiaoqiao, Yunjian, Life, Jinkoujian, Langjian, Yangyuanqing, Caizhiji, Baiyao Health, Leopard Seven, Qiancaotang, Qiancao Meizi, and Tianzihong. The company, established in 1902, maintains its principal offices in Kunming, China.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 000538.SZ is 68 and suggests 35% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

13.06.2026 01:04

SpaceX shares slowed before closing in first trading since record IPO

13.06.2026 00:44

Retail investors bought $15 billion worth of SpaceX stock. Demand was at least 6 times that amount

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026